Conference Coverage
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:00:00
- More information
Informações:
Synopsis
Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.
